Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in theSCN9Agene, encoding a voltage-gated sodium channel
Authors:
- 13 November 2009
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 34 (8) , e640-e642
Abstract
Primary erythermalgia (erythromelalgia) is a rare autosomal dominant condition characterized by intermittent attacks of erythema, increased skin temperature and severe burning pain in the extremities, in a bilateral symmetrical distribution. Mutations in the SCN9A gene, which encodes a voltage‐gated sodium channel have been shown to cause this disease. We report a family identified to have a mutation in the SCN9A gene, in which one severely affected family member has responded to the therapeutic combination of gabapentin and carbamazepine treatment.Keywords
This publication has 8 references indexed in Scilit:
- Primary Erythermalgia as a Sodium ChannelopathyArchives of Dermatology, 2008
- Antiepileptic Drugs in the Treatment of Neuropathic PainDrugs, 2007
- Inherited erythermalgiaNeurology, 2006
- SCN9A Mutations Define Primary Erythermalgia as a Neuropathic Disorder of Voltage Gated Sodium ChannelsJournal of Investigative Dermatology, 2005
- Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgiaJournal of Medical Genetics, 2004
- The Primary Erythermalgia–Susceptibility Gene Is Located on Chromosome 2q31-32The American Journal of Human Genetics, 2001
- Erythromelalgia Pain Managed with GabapentinAnesthesiology, 1997
- Three types of erythromelalgia.BMJ, 1990